Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood–brain barrier in rats

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 1885-1898

  Valiante, Salvatore ^a   Falanga, Annarita ^a   Cigliano, Luisa ^a   Iachetta, Giuseppina ^a   Busiello, Rosa Anna ^a   La Marca, Valeria ^a   Galdiero, Massimiliano ^a   Lombardi, Assunta ^a   Galdiero, Stefania ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Astrocytes; Blood brain barrier; Drug delivery; Neurons; Peptide

Indexed keywords

GH625 PROTEIN; GLYCOPROTEIN; NANOCARRIER; NANOPARTICLE; PROTEIN; TILETAMINE PLUS ZOLAZEPAM; UNCLASSIFIED DRUG; DRUG CARRIER; GH625 PEPTIDE, HERPES SIMPLEX VIRUS TYPE I; PEPTIDE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LIVER; MALE; MITOCHONDRIAL RESPIRATION; MTT ASSAY; NERVE CELL; NEUROBLASTOMA CELL LINE; NONHUMAN; PEPTIDE SYNTHESIS; RAT; SINGLE DRUG DOSE; ANIMAL; BRAIN CHEMISTRY; CELL LINE; CHEMISTRY; METABOLISM; NANOMEDICINE;

HUMAN HERPESVIRUS 1; RATTUS;

ANIMALS; ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN CHEMISTRY; CELL LINE; DRUG CARRIERS; LIVER; NANOMEDICINE; NEURONS; PEPTIDES; RATS; VIRAL ENVELOPE PROTEINS;

EID: 84925967576     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S77734     Document Type: Article

References (35)

1. Bertrand N, Leroux J-C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release. 2012;161(2):152-163.
2. Dinda SC, Pattnaik G. Nanobiotechnology-based drug delivery in brain targeting. Curr Pharm Biotechnol. 2014;14(15):1264-1274.
3. Moros M, Mitchell SG, Grazu V, de la Fuente JM. The fate of nanocarriers as nanomedicines in vivo: important considerations and biological barriers to overcome. Curr Med Chem. 2013;20(22):2759-2778.
4. Bernacki J, Dobrowolska A, Nierwinska K, Malecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep. 2008;60(5):600-622.
5. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014;9:795-811.
6. Dominguez A, Suarez-Merino B, Goni-de-Cerio F. Nanoparticles and blood-brain barrier: the key to central nervous system diseases. J Nanosci Nanotechnol. 2014;14(1):766-779.
7. Xu G, Mahajan S, Roy I, Yong KT. Theranostic quantum dots for crossing blood-brain barrier and providing therapy of HIV-associated encephalopathy. Front Pharmacol. 2013;4:140.
8. Gabathuler R. Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier. Ther Deliv. 2010;1(4):571-586.
9. Jones AT. Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides. Int J Pharm. 2008;354(1-2):34-38.
10. Galdiero S, Vitiello M, Falanga A, Cantisani M, Incoronato N, Galdiero M. Intracellular delivery: exploiting viral membranotropic peptides. Curr Drug Metab. 2012;13(1):93-104.
11. Vonesch C, Unser M. A fast thresholded landweber algorithm for wavelet-regularized multidimensional deconvolution. IEEE Trans Image Process. 2008;17(4):539-549.
12. Galdiero S, Vitiello M, D'Isanto M, et al. The identification and characterization of fusogenic domains in herpes virus glycoprotein B molecules. Chembiochem. 2008;9(5):758-767.
13. Galdiero S, Falanga A, Vitiello M, et al. The presence of a single N-terminal histidine residue enhances the fusogenic properties of a membranotropic peptide derived from herpes simplex virus type 1 glycoprotein H. J Biol Chem. 2010;285(22):17123-17136.
14. Galdiero S, Falanga A, Vitiello M, et al. Analysis of a membrane interacting region of herpes simplex virus type 1 glycoprotein H. J Biol Chem. 2008;283(44):29993-30009.
15. Galdiero S, Falanga A, Morelli G, Galdiero M. g H625: a milestone in understanding the many roles of membranotropic peptides. Biochim Biophys Acta. 2015;1848(1 Pt A):16-25.
16. Falanga A, Vitiello MT, Cantisani M, et al. A peptide derived from herpes simplex virus type 1 glycoprotein H: membrane translocation and applications to the delivery of quantum dots. Nanomedicine. 2011;7(6):925-934.
17. Smaldone G, Falanga A, Capasso D, et al. g H625 is a viral derived peptide for effective delivery of intrinsically disordered proteins. Int J Nanomedicine. 2013;8:2555-2565.
18. Tarallo R, Accardo A, Falanga A, et al. Clickable functionalization of liposomes with the g H625 peptide from herpes simplex virus type I for intracellular drug delivery. Chemistry. 2011;17(45):12659-12668.
19. Guarnieri D, Falanga A, Muscetti O, et al. Shuttle-mediated nanoparticle delivery to the blood-brain barrier. Small. 2013;9(6):853-862.
20. Carberry TP, Tarallo R, Falanga A, et al. Dendrimer functionalization with a membrane-interacting domain of herpes simplex virus type 1: towards intracellular delivery. Chemistry. 2012;18(43):13678-13685.
21. Falanga A, Tarallo R, Galdiero E, Cantisani M, Galdiero M, Galdiero S. Review of a viral peptide nanosystem for intracellular delivery. Int J Nanomedicine. 2013;7(1):071599.
22. Rapaport D, Shai Y. Interaction of fluorescently labeled pardaxin and its analogues with lipid bilayers. J Biol Chem. 1991;266(35):23769-23775.
23. Baschong W, Suetterlin R, Laeng RH. Control of autofluorescence of archival formaldehyde-fixed, paraffin-embedded tissue in confocal laser scanning microscopy (CLSM). J Histochem Cytochem. 2001;49(12):1565-1572.
24. Viegas MS, Martins TC, Seco F, do Carmo A. An improved and cost-effective methodology for the reduction of autofluorescence in direct immunofluorescence studies on formalin-fixed paraffin-embedded tissues. Eur J Histochem. 2007;51(1):59-66.
25. Jaskolski F, Mulle C, Manzoni OJ. An automated method to quantify and visualize colocalized fluorescent signals. J Neurosci Methods. 2005;146(1):42-49.
26. Lanni A, Moreno M, Lombardi A, Goglia F. Calorigenic effect of diiodothyronines in the rat. J Physiol. 1996;494 Pt 3:831-837.
27. Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, Tian XQ. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine. 2014;9:2241-2257.
28. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1):35-58.
29. Demeule M, Régina A, Annabi B, Bertrand Y, Bojanowski M, Béliveau R. Brain endothelial cells as pharmacological targets in brain tumors. Mol Neurobiol. 2004;30(2):157-183.
30. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12(1-2):54-61.
31. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88(3):637-647.
32. Hall W, Doolittle N, Daman M, et al. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol. 2006;77(3):279-284.
33. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A. 1994;91(2):664-668.
34. Schutze-Redelmeier MP, Gournier H, Garcia-Pons F, et al. Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. J Immunol. 1996;157(2):650-655.
35. Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood-brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull. 2003;60(3):297-306.